Drug intelligence / Profile preview

HLBP-037

Development stage: Preclinical
Lead developer: HLB Pharma
Administration: Parenteral

Overview

HLBP-037 is a preclinical-stage long-acting injectable (LAI) candidate being developed by HLB Pharma for the treatment of dementia. The drug utilizes the company's proprietary SMEB (Sustained-release Microsphere Embedding) technology, which is designed to encapsulate active pharmaceutical ingredients within biodegradable polymer microspheres to enable controlled, long-term release. This formulation platform aims to improve medication adherence and maintain stable plasma concentrations in patients with cognitive impairment, potentially reducing the burden of daily oral dosing. While the specific active pharmaceutical ingredient (API) and molecular target have not been publicly disclosed, the program is a key component of HLB Pharma's central nervous system (CNS) pipeline.

Beyond the preview

Go deeper on HLBP-037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLBP-037.

Explore the full profile